Diya Bhalla

Diya Bhalla

Auto-generated profile, based on publicly available information

Diya Bhalla

Department of Bioinformatics, BioNome, Bengaluru, Karnataka, 560043, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2024 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
DBDiya Bhalla
Diya Bhalla
SDSusha Dinesh
Susha Dinesh
SSSAMEER SHARMA
SAMEER SHARMA
GSGonchigar Jayanna Sathisha
Gonchigar Jayanna Sathisha

1 June 2025 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Closed access
PDF file
EPEsha Patel
Esha Patel
ANAjay Nair
Ajay Nair
SSSAMEER SHARMA
SAMEER SHARMA
DBDiya Bhalla
Diya Bhalla
KSKeerthana Shyam
Keerthana Shyam
SDSusha Dinesh
Susha Dinesh
Introduction: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of benign tumors due to mutations in the NF1 gene, which encodes the tumor suppressor neurofibromin. This study aimed to identify novel inhibitors of neurofibromin through drug repurposing of clinical trial compounds from the Zinc15 database. Method: Utilizing advanced in silico techniques, we conducted molecular docking via PyRx and molecular dynamics simulations with GROMACS. Among the compounds analyzed, ZINC000261527152 (Tetrodotoxin) emerged as a promising candidate due to its binding affinity to NF1. Tetrodotoxin formed stable conventional and carbon-hydrogen bonds with key residues, including GLU 981, GLY 984, GLN 985, SER 1030, SER 1561, and ASN 1563. Molecular dynamics simulations confirmed the stability of the Tetrodotoxin- NF1 complex, with favorable RMSD, RMSF, radius of gyration (Rg), and solvent- accessible surface area (SASA) values over a 100 ns simulation period. Result: These results suggest that Tetrodotoxin could effectively inhibit neurofibromin, presenting a novel therapeutic approach for neurofibromatosis. However, despite the promising computational findings, further experimental validation through in vitro and in vivo studies is essential to confirm the efficacy and safety of Tetrodotoxin as a treatment for NF1. Conclusion: This research underscores the utility of computational drug repurposing methodologies and their role in accelerating the discovery of novel treatments for genetic disorders, particularly neurofibromatosis, thereby potentially improving patient outcomes and quality of life.